$CARL

Carlsmed, Inc. Statistics – LS:A41CM7

This page provides financial statistics for Carlsmed, Inc. (LS:A41CM7), a company listed on the Lang & Schwarz Tradecenter. It details various annual and quarterly key financial stats and ratios, including valuation, profitability, liquidity, solvency ratios, and per-share metrics, although most data fields are currently listed as unavailable. The page serves as a hub for users to find market capitalization, P/E Ratio, EPS, ROI, and other financial information for Carlsmed.

Original reporting
Published May 11, 2026, 12:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 11, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CARL
Neutral
low confidence
Mentioned
$CARL
alphai data visualization · based on TradingView
Decision brief

The 30-second read

$CARLNeutralLow
01

Why it matters

The limited financial data constrains the ability to make informed trading decisions.

02

Market read

The news has minimal immediate impact on the market due to the scarcity of actionable financial information.

03

What to watch

Potential upcoming disclosures or developments not yet reflected in the data could influence future performance.

Timing: low

Background

This news provides a snapshot of Carlsmed, Inc.'s financial statistics, which are currently limited.

Company-level read

Ticker impact

$CARLNeutralLow confidence
Context

The financial statistics for Carlsmed, Inc. (LS:A41CM7) are currently limited, with most key metrics unavailable, which constrains detailed analysis.

Expected impact

No significant immediate price movement expected due to lack of actionable data.

Evidence & confidence

The absence of current financial metrics and market data reduces confidence in predicting short-term price movements.

Market effects

The lack of detailed financial data suggests limited sector-wide impact.

Minimal regional impact due to limited data and relevance.

Negligible global market influence.

Counterpoint

While current data is limited, some traders may interpret the lack of negative signals as a cautious positive indicator.

Key entities

  • Carlsmed, Inc.

    A company listed on the Lang & Schwarz Tradecenter with limited available financial data.

Related articles

$CARLHigh

CARLSMED, INC. (CARL): Results of Operations and Financial Condition

CARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 carl-ex99_1.htm EX-99.1 EX-99.1 Carlsmed ® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 milli

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.